title: P-CHOP: cisplatin (P) added to the standard CHOP regimen as first-line treatment for aggressive non-Hodgkin lymphoma: a single-institution phase II study.
abstract: We designed the P-CHOP regimen, which involves the addition of cisplatin (P) to the standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen, and investigated its activity and its toxicities in a single institution phase II study. Twenty-two consecutive patients with untreated, aggressive, stage I-IV non-Hodgkin lymphoma were enrolled in the study. Cisplatin was administered at a dose of 40 mg/m2 on days 1 and 2, every 3 weeks; the dose and schedule of the other agents were identical to those used in the standard CHOP regimen. The complete remission (CR) rate was 86% in eligible and 80% in all the treated patients, which compares favorably with the CR rates of two recent randomized studies of CHOP versus other regimens. P-CHOP is an innovative regimen for the front-line treatment of aggressive non-Hodgkin lymphoma. It is feasible and warrants further research, which would ideally take the form of a randomized comparison of P-CHOP and CHOP, possibly with the addition of rituximab in both arms.
authors.affiliation: Medical Oncology Division, Azienda Ospedaliera Universitaria, Parma, Italy. giorgio.cocconi@tin.it
authors.forename: Giorgio
authors.initials: G
authors.lastname: Cocconi
authors.forename: Vittorio
authors.initials: V
authors.lastname: Franciosi
authors.forename: Anna
authors.initials: A
authors.lastname: Dodero
authors.forename: Alessandra
authors.initials: A
authors.lastname: Bologna
authors.forename: Giovanna
authors.initials: G
authors.lastname: Vasini
authors.forename: Vincenzo
authors.initials: V
authors.lastname: De Lisi
authors.forename: Beatrice
authors.initials: B
authors.lastname: Di Blasio
authors.forename: Guido
authors.initials: G
authors.lastname: Ceci
authors.forename: Roberta
authors.initials: R
authors.lastname: Camisa
authors.forename: Stefano
authors.initials: S
authors.lastname: Cascinu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage*; D012074:Remission Induction; D016019:Survival Analysis; D014750:Vincristine / Q000008:administration & dosage*
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D011241:Prednisone